

# Involvement of the mTOR Signaling Pathway in the Regulation of Antiretroviral Drug Efflux Transporters in CD4+ T-cells Exposed to an HIV Pseudotype

Sana-Kay Whyte-Allman,<sup>1</sup> Rupert Kaul,<sup>2</sup> and Reina Bendayan<sup>1</sup>

<sup>1</sup>Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.

<sup>2</sup>Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

**Presenter: Reina Bendayan**

**Department of Pharmaceutical Sciences**

**University of Toronto**

**Email: [r.bendayan@utoronto.ca](mailto:r.bendayan@utoronto.ca)**


---

29th Annual Canadian Conference on HIV/AIDS Research (CAHR 2021)

Conflict of Interest Disclosure: I have no conflicts of interest

## BACKGROUND

- ❖ ATP-binding cassette (ABC) drug efflux transporters could contribute to low antiretroviral drug (ARV) intracellular concentrations in HIV-1 target tissues and cells.<sup>1</sup>
- ❖ Furthermore, studies have reported that the expression and function of these transporters could be induced in activated and/or HIV-infected T-cells.<sup>2</sup>
- ❖ The mammalian target of rapamycin (mTOR) signaling pathway is activated following HIV-1 infection and T-cell activation.<sup>3</sup>
- ❖ Therefore, we examined the regulation of ABC drug efflux transporters by mTOR, and their potential contribution to the inflammatory response following exposure of T-cells to an HIV pseudotype (pHIV<sub>NL4-3</sub>).



**Figure 1.** Potential involvement of mTOR in the regulation of drug efflux transporters and inflammatory response in HIV-infected T-cells.

1. Whyte-Allman and Bendayan (2020). HIV-1 Sanctuary Sites—the Role of Membrane-Associated Drug Transporters and Drug Metabolic Enzymes. *AAPS J*, 22 (118).

2. Turriziani O et al., (2008). Expression Levels of MDR1 , MRP1 , MRP4 , and MRP5 in Peripheral Blood Mononuclear Cells From HIV Infected Patients Failing Antiretroviral Therapy. *J Med Virol*, 771 (766-771).

3. Kumar B et al., (2017). Hyperactivation of mammalian target of rapamycin complex 1 by HIV-1 is necessary for virion production and latent viral reactivation. *FASEB J*, 31(180-191).


# HYPOTHESIS

ABC transporters are upregulated in activated T-cells through the mTOR-mediated signaling pathway following exposure to pHIV<sub>NL4-3</sub>.


# METHODS

## A) HIV<sub>NL4-3</sub> –VSVG Pseudotype (pHIV<sub>NL4-3</sub>)

- Provided by Dr. Alan Cochrane, Dept. Molecular Genetics, UofT
- Deletion in regions of pol gene prevents viral replication.
- Modified with a GagzipGFP fusion to express EGFP.
- Pseudotyped with VSV envelope glycoprotein (VSVG).




## B)



# mTOR Inhibitor OSI-027 Reverses pHIV<sub>NL4-3</sub> Inductive Effects on Transporters and T-cell Activation

- ✓ pHIV<sub>NL4-3</sub> increases the expression of ABC transporters and T-cell activation marker CD69 in CD4<sup>+</sup> T-cells; this involves regulation by the mTOR signaling pathway.




**Figure 2.** Expression (MFI; median fluorescence intensity) of P-gp, BCRP, MRP1, pmTOR and CD69 in untreated (vehicle control), pHIV<sub>NL4-3</sub>, and/or OSI-027 treated CD4<sup>+</sup> T-cells. Representative histograms (top) and corresponding bar charts (bottom) are shown.

# mTOR, P-gp and MRP1 are Involved in Proinflammatory Cytokine Release from pHIV<sub>NL4-3</sub> Exposed PBMCs.

✓ Treatment with mTOR inhibitor OSI-027 decreased cytokine levels in supernatants of pHIV<sub>NL4-3</sub> exposed PBMCs.



✓ Pharmacological inhibition of P-gp or MRP1 decreased cytokine levels in supernatants of pHIV<sub>NL4-3</sub> exposed PBMCs.



**Figure 3.** Proinflammatory cytokine concentrations in PBMC supernatants collected following exposure to vehicle, pHIV<sub>NL4-3</sub>, and/or OSI-027 for 48h.

## CONCLUSION

We present novel data demonstrating that ABC drug efflux transporters are upregulated via mTOR signaling in CD4+ T-cells exposed to pHIV<sub>NL4-3</sub>. These transporters could limit ARV permeability in HIV target T-cells, as well as potentially contribute to HIV-associated proinflammatory cytokine secretion. This study provides a basis to further assess the role and regulation of ARV drug efflux transporters in T-cell activation and inflammatory response, in the context of HIV infection.



**Figure 4.** Proinflammatory cytokine concentrations in PBMC supernatants collected following exposure to vehicle, pHIV<sub>NL4-3</sub>, and/or P-gp inhibitors verapamil and PSC833 (A) or MRP1 inhibitor MK571 (B) for 48h.